The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery

  • Authors:
    • Gaokun Zhang
    • Shuang Liu
    • Lieying Yang
    • Yanqing Li
  • View Affiliations

  • Published online on: December 15, 2017     https://doi.org/10.3892/etm.2017.5639
  • Pages:2177-2181
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The aim of the present study is to determine the efficacy of dexamethasone (DEX) vs. indomethacin (IND) and ciprofloxacin (CIP) in modulating immediate inflammation following cataract surgery. A total of 644 patients with cataract were recruited and inflammation was investigated during the perioperative period. The management protocol was similar in both groups. Each drug was given four times a day for 30 days starting 7 days prior to surgery. The primary efficacy criteria for evaluation were the reduction in anterior chamber (AC) flare and AC inflammation score, in addition, a different secondary efficacy and safety evaluation criteria were maintained. The results demonstrated that the average inflammation score was 1.2±0.8 in the DEX group, which was significantly lower compared with the IND (1.9±0.7) and CIP (1.8±0.6) groups. Intra‑ocular pressure was decreased following treatment with DEX, while intra‑ocular pressure was slightly increased in the IND (1.9±0.7) and CIP (1.8±0.6) groups. The final visual outcomes for patients postcataract surgery were clinically superior in the DEX group compared with that of the IND and CIP groups (P=0.034 and P=0.042, respectively), but there was no significant difference between the ND and CIP groups (P=0.78). Outcomes indicated that AC inflammation, conjunctival hyperaemia, corneal and lid oedema, ocular infection, pain, photophobia, and tearing were significantly improved in each group. No significant poor local tolerance or adverse reaction was observed in the DEX, IND and CIP groups. In conclusion, the outcomes of the present study suggest that DEX serves an important role in the clinical pharmaceutical treatment of patients with cataract surgery.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, G., Liu, S., Yang, L., & Li, Y. (2018). The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery. Experimental and Therapeutic Medicine, 15, 2177-2181. https://doi.org/10.3892/etm.2017.5639
MLA
Zhang, G., Liu, S., Yang, L., Li, Y."The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery". Experimental and Therapeutic Medicine 15.2 (2018): 2177-2181.
Chicago
Zhang, G., Liu, S., Yang, L., Li, Y."The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery". Experimental and Therapeutic Medicine 15, no. 2 (2018): 2177-2181. https://doi.org/10.3892/etm.2017.5639